文献速递肝病消化道出血

弹簧圈或封堵器辅助逆行经静脉闭塞术(CARTO/PARTO)治疗门静脉高压性静脉曲张出血:多中心真实世界10年回顾性研究

Coil or plug-assisted retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multicenter, real-world 10-year retrospective study.
PubMed 文献 · Hepatology · 2025-02-05

这项多国多中心回顾性研究纳入5国13中心311例接受CARTO/PARTO治疗胃静脉曲张的患者,中位总生存期99个月,1、3、5、7、10年累积总生存率分别为98%、80%、68%、52%、33%。预防性CARTO/PARTO的总生存期优于活动性出血者(p=0.00035),高MELD评分、合并肝细胞癌、GOV2型、食管静脉曲张出血史、高总胆红素和高氨血症为独立预后因素。

要点

  • CARTO/PARTO治疗后10年累积总生存率为33%,中位总生存期99个月。
  • 预防性CARTO/PARTO的总生存期优于活动性出血者(p=0.00035)。
  • MELD评分>27者死亡率92.6%,显著高于较低MELD评分者(p<0.001)。

核心结论

  • CARTO和PARTO具有优异的长期生存和临床结局,但高MELD评分、合并肝细胞癌和并存食管静脉曲张会对这些结局产生负面影响。

研究设计与样本

  • 多国多中心回顾性研究,纳入2012年5月至2024年7月间5国13中心311例接受CARTO/PARTO治疗胃静脉曲张的患者(女性41%,CARTO占69%)。

主要发现

  • 累积1、3、5、7、10年总生存率分别为98%、80%、68%、52%、33%,中位总生存期99个月。
  • 预防性CARTO/PARTO的总生存期优于活动性出血者(p=0.00035)。
  • 累积1、3、5、7、10年胃静脉曲张再出血率分别为0.9%、3.2%、4.0%、4.5%、5.4%。
  • 总体技术成功率为96.5%,临床成功率为95.3%,10年主要并发症发生率为4.5%。
  • MELD评分>27者死亡率92.6%,显著高于较低MELD评分者(p<0.001)。

关键数值与推荐

  • 总生存期的独立预后因素包括:高MELD评分、合并肝细胞癌、治疗GOV2型、食管静脉曲张出血史、高总胆红素和高氨水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Coil-assisted retrograde transvenous obliteration (CARTO) and plug-assisted retrograde transvenous obliteration (PARTO) are well-accepted treatments for gastric variceal bleeding. However, long-term (>2 y) clinical outcomes have yet to be studied. In this study, we investigated long-term clinical outcomes, including overall survival (OS) in 10 years. APPROACH AND RESULTS: We performed a multinational, multicenter, retrospective study of CARTO/PARTO in gastric varices treatments between May 2012 and July 2024. The primary study outcomes were a long-term OS and prognostic factors of CARTO/PARTO. The secondary outcomes were long-term clinical/technical success, complications, and clinical changes including portal hypertensive symptoms. A total of 311 patients (41% female; 69% CARTO) from 13 centers in 5 countries were included. The cumulative 1-, 3-, 5-, 7-, and 10-year OS rates were 98%, 80%, 68%, 52%, and 33%, respectively, with a median OS of 99 months. Prophylactic CARTO/PARTO showed a better OS than CARTO/PARTO for active bleeding ( p =0.00035). The independent prognostic factors of OS were having high pre-MELD, concurrent HCC, treating GOV2, history of esophageal variceal bleeding, high pre-TBili, and ammonia levels. Notably, a high pre-MELD score >27 had a significantly higher mortality rate (92.6%) than a lower pre-MELD score ( p <0.001). The overall cumulative 1-, 3-, 5-, 7-, and 10-year recurrent gastric varices bleeding rates were 0.9%, 3.2%, 4.0%, 4.5%, and 5.4%, respectively. The overall technical and clinical success rates were 96.5% and 95.3%, respectively, with a 4.5% major complication rate over 10 years. CONCLUSIONS: CARTO and PARTO have excellent long-term survival and clinical outcomes. However, these are negatively affected by high MELD scores, concomitant HCC, and coexisting esophageal varices.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lee EW, Saab S, Eghbalieh N, et al. Coil or plug-assisted retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multicenter, real-world 10-year retrospective study. Hepatology. 2025. PMID: 39908474. doi:10.1097/HEP.0000000000001255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。